MHRA approves lurbinectedin for adults with extensive‑stage small cell lung cancer
MHRA approved lurbinectedin (Zepzelca) for maintenance treatment of adults with extensive‑stage small cell lung cancer whose disease has not progressed fol…
Impact analysis · 38/100 · AI-assisted priority
This score prioritizes research; it does not predict an outcome. Method and limitations.
What happened
MHRA approved lurbinectedin (Zepzelca) for maintenance treatment of adults with extensive‑stage small cell lung cancer whose disease has not progressed following first‑line induction therapy with atezolizumab, carboplatin and etoposide. The marketing authorisation was granted to Pharma Mar S.A. via the International Recognition Procedure Route B following a CHMP opinion.
Quantitative evidence
- 483 adults in main study
- Overall survival 13.2 versus 10.6 months
- Progression‑free survival 5.4 versus 2.1 months
Affected entities
Analysis
The following contextual analysis is AI-assisted and separated from the reported primary-source record above.
Scientific context
Lurbinectedin is a DNA‑targeting agent that induces cancer cell death and was studied in combination with atezolizumab after induction treatment. The trial showed survival benefit in maintenance therapy.
Market context
Pharma Mar gains UK marketing approval for a new maintenance option in ES‑SCLC, potentially addressing unmet need but market impact remains limited due to modest uptake assumptions.
Legal and regulatory context
Approval followed the International Recognition Procedure with reference to a CHMP positive opinion; this is a final marketing authorisation by MHRA.
Sources
For informational use only. Verify decisions against the linked regulator or primary source.
Evidence & limits
Source: Open the source record
- Record identifier
- cd56559065df648918dcf561225e195ed6a5aa4aa9d007b666b12bff245e1d41
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- 2026-09-23T21:30:26Z
What it supports. The linked authority’s action, within the product, indication, jurisdiction, and procedural stage stated in that record.
Limits. A committee opinion, draft, or announcement does not by itself establish final authorization. The summary and contextual analysis are AI-assisted; a source link does not establish human review.
Connection basis. Related profiles are normalized name mentions in article text. A mention does not establish a legal relationship.